Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?

Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Warnke, Clemens, Menge, Til, Hartung, Hans-Peter, Racke, Michael K., Cravens, Petra D., Bennett, Jeffrey L., Frohman, Elliot M., Greenberg, Benjamin M., Zamvil, Scott S., Gold, Ralf, Hemmer, Bernhard, Kieseier, Bernd C., Stüve, Olaf
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/
https://ncbi.nlm.nih.gov/pubmed/20697042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы